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Rationale: The ubiquitin–proteasome system (UPS) is responsible for skeletal
muscle atrophy. We showed earlier that the transcription factor EB (TFEB) plays
a role by increasing E3 ubiquitin ligase muscle really interesting new gene-finger
1(MuRF1)/tripartite motif-containing 63 (TRIM63) expression. MuRF 1 ubiquitinates
structural proteins and mediates their UPS-dependent degradation. We now
investigated how TFEB-mediated TRIM63 expression is regulated.
Objective: Because protein kinase D1 (PKD1), histone deacetylase 5 (HDAC5), and
TFEB belong to respective families with close structural, regulatory, and functional
properties, we hypothesized that these families comprise a network regulating
TRIM63 expression.
Methods and Results: We found that TFEB and transcription factor for
immunoglobulin heavy-chain enhancer 3 (TFE3) activate TRIM63 expression. The class
IIa HDACs HDAC4, HDAC5, and HDAC7 inhibited this activity. Furthermore, we could
map the HDAC5 and TFE3 physical interaction. PKD1, PKD2, and PKD3 reversed the
inhibitory effect of all tested class IIa HDACs toward TFEB and TFE3. PKD1 mediated
nuclear export of all HDACs and lifted TFEB and TFE3 repression. We also mapped
the PKD2 and HDAC5 interaction. We found that the inhibitory effect of PKD1 and
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PKD2 toward HDAC4, HDAC5, and HDAC7 was mediated by their phosphorylation and
14-3-3 mediated nuclear export.
Conclusion: TFEB and TFE3 activate TRIM63 expression. Both transcription factors
are controlled by HDAC4, HDAC5, HDAC7, and all PKD-family members. We propose
that the multilevel PKD/HDAC/TFEB/TFE3 network tightly controls TRIM63 expression.
Keywords: muscle atrophy, protein kinase D, HDAC = histone deacetylase, transcription factor EB, TFE3, muscle
ring finger protein 1
INTRODUCTION
Muscle mass is mainly regulated by an equilibrium of protein
synthesis and degradation. Both muscle atrophy and hypertrophy
occur physiologically and under disease conditions (Hershko
and Ciechanover, 1998; Ciechanover, 2006; Schmidt et al.,
2014; Wollersheim et al., 2014). The ubiquitin–proteasome
system (UPS) is the principal protein-degrading system in
muscle and largely responsible for the degradation of contractile
proteins (Medina et al., 1995; Wing et al., 1995; Voisin
et al., 1996; Ciechanover, 2006; Witt et al., 2008). Substrate
protein ubiquitination is mediated by E3 ubiquitin-ligases that
are specificity assuring and rate-limiting enzymes within the
UPS (Hershko and Ciechanover, 1998; Ciechanover, 2006).
Polyubiquitinated target proteins are then degraded by the 26S
proteasome (Ciechanover, 2006). The UPS is activated during
muscle atrophy leading to declining of structural and contractile
proteins, most notably myosin heavy chain (MHC) (Fielitz et al.,
2007), resulting in a reduction of muscle mass and function. The
E3 ligase, muscle really interesting new gene-finger 1 (MuRF1),
was identified as a major atrogene and is restricted to skeletal
muscle and the heart (Bodine et al., 2001a). MuRF1 was shown
to mediate ubiquitination and UPS-dependent degradation of
structural proteins, such as alpha-actin, troponin I, troponin T,
telethonin, titin, nebulin, the nebulin-related-anchoring protein,
myosin light chain 2, myotilin, and T-cap (Kedar et al.,
2004; Witt et al., 2005; Polge et al., 2011, 2018). Importantly,
MuRF1 is also involved in muscular energy metabolism by
degradation of non-structural proteins, such as muscle-type
creatine kinase, glucocorticoid modulatory element binding
protein-1, and 3-hydroxyisobutyrate dehydrogenase in striated
muscles (McElhinny et al., 2002; Koyama et al., 2008). Numerous
studies showed that the tripartite motif-containing 63 (TRIM63)
gene expression, encoding MuRF1, is increased rapidly and
strongly during various physiological and pathological atrophy
conditions (Bodine et al., 2001a). The multitude of its target
proteins, together with its strong transcriptional regulation,
highlights the importance of MuRF1 in muscle homeostasis. To
evaluate the transcriptional control of TRIM63, we performed
a complementary DNA (cDNA)-expression screen to identify
Abbreviations: HDAC, histone deacetylase-5; MuRF, Muscle really interesting
new gene (RING)-finger containing protein; MiT/TFE, Microphthalmia-
associated transcription factor/transcription factor E; PKD, Protein Kinase D; TF,
transcription factor; TFEB, transcription factor EB; TFE3, Transcription factor for
immunoglobulin heavy-chain enhancer 3; TRIM63, Tripartite motif-containing
63 (mouse gene encoding MuRF1).
regulators of TRIM63 expression and identified the basic helix-
loop-helix leucine zipper (bHLH-LZ) transcription factor EB
(TFEB) as a novel TRIM63 regulator (Du Bois et al., 2015). We
found that TFEB binds to specific, well-conserved, enhancer box
(E-box) DNA motifs in the TRIM63 promoter that are close to
its transcription start site. We reported that TFEB activity was
inhibited via interaction with the class IIa histone deacetylase
(HDAC) 5. We also showed that inhibition of TFEB by HDAC5
was attenuated by the stress-dependent serine/threonine kinase
protein kinase D (PKD) 1, which interacted with HDAC5 and
mediated its phosphorylation and 14-3-3 chaperone mediated
nuclear export. This PKD1/HDAC5/TFEB axis controlled the
expression of TRIM63 and was found to be important in
angiotensin II-induced myocyte atrophy in vitro and muscle
atrophy in vivo (Du Bois et al., 2015).
Recent reports, however, indicated that this pathway might
not be as specific as we believed. For example, TFEB belongs
to the microphthalmia/transcription factor E (MiT/TFE) family
of bHLH-LZ transcription factors (TFs), which also includes
TFE3, TFEC, and microphthalmia-associated transcription factor
(MiTF). All MiT/TFEs recognize a unique E-box motif within the
proximal promoters of lysosomal and autophagy genes (Sardiello
et al., 2009; Palmieri et al., 2011; Martina et al., 2014) and
regulate cellular catabolism and nutrient-dependent lysosomal
response (Settembre et al., 2011; Slade and Pulinilkunnil, 2017).
Importantly, TFEB and TFE3 were found to have partially
redundant functions and to regulate overlapping sets of genes
(Pastore et al., 2016). However, whether or not TFE3 or MiTF can
activate TRIM63 expression is not known. In addition, the class
IIa HDACs (HDAC4, HDAC5, HDAC7, and HDAC9) are highly
expressed in the heart and skeletal muscle, and their interaction
with the myocyte enhancer factor 2 (MEF2) TF decreases the
expression of MEF2 target genes (Lu et al., 2000a,b; McKinsey
et al., 2000; Zhang et al., 2002). If other class IIa HDACs inhibit
the activity of TFEB or TFE3 is also unclear. Finally, PKD1
belongs to a family of calmodulin-calcium-dependent serine-
threonine kinases (termed PKD1, PKD2, and PKD3). These
kinases are important in cell growth, differentiation, migration,
and apoptosis (Rozengurt et al., 2005). The close structural
relationship of the PKD family members suggested that they
might phosphorylate overlapping targets. Indeed, all three family
members PKD1, PKD2, and PKD3 were shown to phosphorylate
HDAC5 (Huynh and McKinsey, 2006). However, any effect
on TFEB or TFE3-mediated TRIM63 expression is uncertain.
Because PKD1, HDAC5, and TFEB belong to respective families
with close structural, regulatory, and functional properties, we
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hypothesized that other family members could also be involved
in the regulation of TRIM63 expression.
MATERIALS AND METHODS
Cell Culture, Complementary DNA
Expression Plasmids, and Luciferase
Reporter Assays
Cell culture experiments of murine myoblasts (C2C12 cells,
ATCC, United States) were performed as previously described
(Langhans et al., 2014; Huang et al., 2017; Zhu et al., 2017).
Briefly, myoblasts were cultured in the growth medium
[Dulbecco’s modified Eagle’s medium (1 g/l glucose, Merck,
Germany), 10% fetal bovine serum (Biochrom GmbH,
Germany), supplemented with penicillin and streptomycin
(Merck, Germany)]. For Western blot analyses, immunostaining
and co-immunoprecipitation experiments, the C2C12 cells
were cultivated on six-well plates, coverslips and 10 cm
dishes, respectively. COS-7 cells were cultured in standard
cell culture conditions using Dulbecco’s modified Eagle
medium (4.5 g/l glucose, L-glutamine, 10% fetal bovine serum,
and penicillin–streptomycin). Cells were seeded in 24-well
plates in triplicates and transfected with cDNA expression
plasmids, vector control, and pGL3-TRIM63_Luc reporter
construct, as indicated, using FuGENE6
R©
(Promega) transfection
reagent according to the manufacturer’s protocol. To control
transfection efficacy, 25 ng of pCMV lacZ (Clontech) was
co-transfected in each sample. Cell pellets were lysed in 200
µl Luciferase Cell Culture Lysis Reagent (Promega). Fifty
microliters of lysate was used for quantification of luciferase
activity and β-galactosidase in a luminometer (FLUOstar
Optima, BMG-Labtech). The Luciferase Assay System (Promega)
was used to quantify the expression of the reporter gene
constructs. Luciferase activity was normalized to fluorescence
measured with the FluoReporter
R©
lacZ/Galactosidase




pcDNA3.1-C-MYC, pcDNA3.1-C-MYC, and pcDNA3.1-
N-FLAG (Vega et al., 2004; Fielitz et al., 2008; Kim et al.,
2008; Du Bois et al., 2015), HDAC5-deletion mutants (Song
et al., 2006; Du Bois et al., 2015), and further constructs
(pGL3-TRIM63_Luc, pGL3-TRIM63_mut_E-box1_Luc,
pGL3-TRIM63_mut_E-box2_Luc, pGL3-TRIM63_mut_E-
box3_Luc, and pCMV lacZ) (Fielitz et al., 2008; Kim et al.,
2008; Du Bois et al., 2015)] were recently published. The cDNA
expression plasmids for human HDAC1 (#13820) (Emiliani
et al., 1998), human HDAC3 (#13819) (Emiliani et al., 1998),
and human calcium/calmodulin-dependent protein kinase
type IV (CamK IV, #126422) (Xie and Black, 2001) were
purchased from Addgene, United States. For the generation
of the cDNA expression vectors pcDNA3.1-TFE3-N-FLAG,
pcDNA3.1-MiTF-N-FLAG, pcDNA3.1-PKD2-CA-N-MYC,
pcDNA3.1-PKD3-CA-N-MYC, pcDNA3.1-PKD2-CA-N-FLAG,
and pcDNA3.1-PKD3-CA-N-FLAG, expressing murine TFE3,
MiTF, constitutive active PKD2 or PKD3 with an N-terminal
FLAG tag or an N-terminal MYC tag, respectively, mouse cDNA
was PCR amplified with the primers shown in Online Table 1
using Advantage HD Polymerase (Takara) and cloned into
pcDNA-3.1-N-MYC or pcDNA-3.1-N-FLAG (both Invitrogen)
using the restriction enzymes indicated and T4 DNA ligase (both
New England Biolabs) according to the manufacturer’s protocol.
All constructs were verified by sequencing. The mammalian
two-hybrid assay was performed as recently published (Chang
et al., 2005; Du Bois et al., 2015).
Immunofluorescence
For immunostaining, C2C12 myoblasts were cultured in
8 chamber polystyrene vessel tissue culture treated glass
slides (BD Biosciences, United States) and fixed with 4%
paraformaldehyde/PBS, permeabilized with 0.2% Triton-X-
100/PBS, and blocked with 2% goat serum/PBS. The following
primary antibodies were used: anti-TFEB antibody (Biolegend,
United States, 1:100), anti-TFE3 antibody (Abnova, 1:50),
anti-PKD1 antibody (Abnova, 1:80), anti-PKD3 antibody
(Sigma-Aldrich, United States 1:100), anti-HDAC4 antibody
(Cell Signaling United Kingdom, 1:100), anti-HDAC5 antibody
(Cell Signaling United Kingdom, 1:100), and anti-HDAC7
antibody (Cell Signaling United Kingdom, 1:100). Alexa fluor 488
Goat Anti-Mouse IgG (H+ L) (Life Technologies, United States,
1:1,000) and Alexa fluor 555 Goat Anti-Rabbit IgG (H + L) (Life
Technologies, United States, 1:1,000) were used as secondary
antibodies. 4′,6-diamidino-2-phenylindole, dihydrochloride
(300 mM, Thermo Fisher Scientific, United States) was used
to stain for nuclei. Immunostained cells were embedded




5′-CCA TCG ATT CTC ATG CAG CCG AGC-3′
TFE3 pcDNA3.1-N-FLAG
reverse (XbaI)
























5′-ATA GTT TAG CGG CCG CCA GAG GAT
GCT GAT GCG CTC-3′
PKD3 pcDNA3.1-CA-N-MYC
forward (ClaI)












5′-CGG AAT TCT CTG CAA ATA ATT CCC
CTC C-3′
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in ProLongTM Gold antifade mountant (Life Technologies,
United States). Images were acquired with a Zeiss LSM 700
confocal microscope and processed with ZEN 2009 (Zeiss)
and Fiji software.
COS-7 cells were plated in six-well plates on sterile coverslips.
At the experimental endpoint, cells were PBS-washed and
fixed in 3.7% formaldehyde for 10 min at room temperature.
Permeabilization and blocking of cells were carried out in a single
step with 0.3% Triton X-100, 0.5% goat serum (Abcam) in PBS
for 1 h at room temperature. Coverslips were incubated with the
specific primary antibody at 4◦C overnight. Secondary antibodies
conjugated with Alexa Fluor
R©
488 or Alexa Fluor
R©
555 were
diluted in PBS and incubated for 2 h at room temperature. 4′,6-
diamidino-2-phenylindole, dihydrochloride (300 mM, Thermo
Fisher Scientific, United States) was used to stain for nuclei.
Immunostained cells were embedded in ProLongTM Gold
antifade mountant (Invitrogen, United States). Images were
acquired with a Zeiss LSM 700 confocal microscope and
processed with ZEN 2009 (Zeiss) and Fiji software.
Protein Extraction and Western Blot
Analysis
Western blot analysis was performed as recently published
(Schmidt et al., 2014; Lodka et al., 2016; Huang et al., 2017;
Zhu et al., 2017). Shortly, cells were lysed in ice-cold extraction
buffer [10-mM Tris-hydrochloride, pH 7.5, 140-mM sodium
chloride, 1-mM ethylenediaminetetraacetic acid, 25% glycerol,
0.5% sodium dodecyl sulfate (SDS), 0.5% Non-idet P-40, 0.1-mM
dithiothreitol, 0.5-mM phenylmethylsulfonyl fluoride, and 100
ng/ml complete ethylenediaminetetraacetic acid-free protease
inhibitor cocktail, ROCHE] and then cleared by centrifugation
(4◦C, 15 min, 12,000 × g). The Bio-Rad Protein Assay was
used to quantitate protein concentration in the supernatant.
Isolated proteins were frozen and stored at −80◦C until usage.
For Western blot analysis, 20 µg protein was separated by
10% SDS polyacrylamide gel electrophoresis and blotted onto
polyvinylidene fluoride or nitrocellulose membranes (GE
Healthcare, United Kingdom). Membranes were incubated
with specific primary antibodies: anti-glyceraldehyde-3-
phosphate dehydrogenase (GAPDH, clone 6C5, Millipore,
United States, 1:10,000), anti-HDAC4 antibody (Cell Signaling,
United Kingdom, 1:1,000), anti-HDAC5 antibody (Cell
Signaling, United Kingdom, 1:1,000), anti-HDAC7 antibody
(Cell Signaling, United Kingdom, 1:1,000), anti-phospho-
HDAC4 (Ser246)/HDAC5 (Ser259)/HDAC7 (Ser155) (Cell
Signaling United Kingdom, 1:1,000), anti-phospho-HDAC4
(Ser632)/HDAC5 (Ser661)/HDAC7 (Ser486) (Cell Signaling
United Kingdom, 1:1,000), anti-DYKDDDDK (FLAG-tag, Cell
Signaling United Kingdom, 1:1,000), and anti-MYC (Millipore,
1:500) and secondary horseradish peroxidase-conjugated
antibodies: anti-mouse IgG (Cell Signaling, United Kingdom,
1:3,000), anti-rabbit IgG (Cell Signaling, United Kingdom,
1:20,000), and anti-goat IgG (Abcam, United Kingdom,
1:3,000). The signalTM was visualized with Super Signal
West Pico Chemiluminescent Substrate (Thermo Fisher
Scientific, United States).
Co-immunoprecipitation
Transfected cells were washed with ice-cold PBS and resuspended
in lysis buffer (50 mM potassium phosphate, 150 mM sodium
chloride, 0.5% Triton X-100, pH 7.4). Lysates were cleared
by centrifugation at 10,000 × g for 10 min at 4◦C. For co-
immunoprecipitation, supernatants were incubated with 30 µl
of prewashed anti-FLAG M2 agarose (Sigma, A2220) for 2 h at
4◦C. Immunoprecipitated proteins were eluted from agarose by
5 min boiling at 95◦C in Laemmli sample buffer (125-mM Tris-
hydrochloride, 10% glycerol, 10% SDS, 130-mM dithiothreitol)
and analyzed by Western blot.
Statistics
All experiments were performed independently and at least three
times using biological triplicates each and technical duplicates for
each biological replicate. Data are shown as mean ± SEM. For all
comparisons, one-way analyses of variance (ANOVAs) followed
by a pairwise Student’s t-test for independent groups were
performed using GraphPad Prism 8.3.0 (GraphPad Software,
Inc.) and Excel 2016 (Microsoft) software. P-values of less
than 0.05 were considered statistically significant (∗P < 0.05;
∗∗P < 0.01; ∗∗∗P < 0.001). Adobe Illustrator, version 16.0.0, was
used for illustrations.
RESULTS
Class IIa Histone Deacetylases 4, 5, and
7 Inhibit Transcription Factor
EB-Mediated Tripartite Motif-Containing
63 Expression
Previously, we showed that TFEB increases the expression of
human TRIM63 by binding to specific E-box elements close to
the transcription start site in its promoter (Du Bois et al., 2015).
We showed that TFEB transcriptional activity was attenuated by
HDAC5 that physically interacted and colocalized with TFEB
in myocytes in vitro (Du Bois et al., 2015). Because HDAC4
and HDAC5 collectively inhibit the activity of the bHLH TF
myogenin toward TRIM63 expression (Moresi et al., 2010), we
hypothesized that other class IIa HDACs reduce the activity of
TFEB on the TRIM63 promoter as well. Using luciferase assays,
we found that HDAC4 (Figure 1A), HDAC5 (Figure 1B), and
HDAC7 (Figure 1C) inhibit TFEB-induced activity of the human
TRIM63 luciferase reporter in a dose-dependent manner. These
data indicate that TFEB-induced TRIM63 expression is inhibited
by not only HDAC5 but also HDAC4 and HDAC7.
Protein Kinase D Family Members
Attenuate Histone Deacetylase-Mediated
Inhibition of Transcription Factor
EB-Induced Tripartite Motif-Containing
63 Expression
Earlier, we reported that PKD1 associates with phosphorylates
and facilitates 14-3-3-mediated nuclear export of HDAC5,
which relives inhibition of TFEB and thereby increases TRIM63
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FIGURE 1 | Class IIa histone deacetylases 4, 5, and 7 inhibit TFEB-induced TRIM63 expression. (A–C) Luciferase assays performed with cell extracts of COS-7 cells
transfected with Hs_TRIM63-Luc (-543 bp), FLAG-TFEB (TFEB) and increasing amounts of (A) MYC-HDAC4 (HDAC4), (B) MYC-HDAC5 (HDAC5), or
(C) MYC-HDAC7 (HDAC7) as indicated or control (-) plasmid. Luciferase activity was normalized to expression of CMV-LacZ and expressed as fold increase. Data
are represented as mean ± SEM. One-way ANOVA P < 0.0001 for (A–C); ###P < 0.005 vs. control transfection with pcDNA3.1; *P < 0.05, **P < 0.01,
***P < 0.005 vs. transfection with TFEB only.
expression (Du Bois et al., 2015). Because the three PKD-family
members PKD1, PKD2, and PKD3 share a high degree of
similarity in their functional domains (Avkiran et al., 2008) and
were shown to phosphorylate HDAC5 (Huynh and McKinsey,
2006), we hypothesized that the PKD-family regulates TFEB
activity by inactivating HDAC4, HDAC5, and HDAC7 as well.
To investigate the effect on HDAC-mediated inhibition of TFEB,
we performed luciferase assays. As already shown, TFEB-induced
TRIM63 activity was inhibited by HDAC4 (Figure 2A), HDAC5
(Figure 2B), and HDAC7 (Figure 2C). In contrast, the class
I HDACs 1 and 3 did not decrease TFEB-induced TRIM63
activity (Supplementary Figure 1A). When we cotransfected
PKD1 (Figures 2A–C, left panels), PKD2 (Figures 2A–C, middle
panels), or PKD3 (Figures 2A–C, right panels), the repressive
effects of all three HDACs were relieved. CamK IV, which
was used as a positive control, also relieved the repressive
effects of HDAC4, HDAC5, and HDAC7 in the same assay
(Supplementary Figure 2A). Our data indicate that the PKD
family converges on HDAC4, HDAC5, and HDAC7 to control
TRIM63 expression. To investigate if the observed effects of
the PKD family onto HDAC-mediated inhibition of TFEB are
due to nuclear export of HDAC4 and HDAC7, we performed
immunocytochemistry experiments. As expected, we observed
colocalization of HDAC5 (Figure 2D, left panel) and also HDAC4
(Figure 2D, middle panel) and HDAC7 (Figure 2D, right panel)
with TFEB in the nucleus. This colocalization is a possible
molecular basis for class IIa HDAC-mediated TFEB inhibition.
When we cotransfected with PKD1, HDAC4, HDAC5, and
HDAC7 translocated to the cytoplasm, whereas TFEB remained
in the nucleus (Figure 2D).
Phosphoserines 246, 467, and 632 in HDAC4 (Backs et al.,
2006), 259 and 498 in HDAC5 (Zhang et al., 2002), and 155,
181, 321, and 449 in HDAC7 (Dequiedt et al., 2005) serve
as binding sites for the chaperone protein 14-3-3 and are
known PKD1 phosphorylation sites. Previously, we confirmed
that PKD1 binds to HDAC5 and phosphorylates its 14-3-3
consensus sites. To investigate if PKD1 has a similar effect
on HDAC4 and HDAC7, we performed a mammalian-two-
hybrid assay using GAL4 upstream activator sequence (UAS)-
luciferase, as published recently (Chang et al., 2005; Du Bois
et al., 2015). This assay was also used to investigate if PKD2
phosphorylates HDAC4, HDAC5, and HDAC7 as well. In this
assay, the N-terminus of HDAC4, HDAC5, or HDAC7 is fused to
the GAL4 DNA-binding domain, and 14-3-3 is fused to the VP16
transactivation domain. Under normal growth conditions, these
HDACs are not phosphorylated in COS-7 cells. Thus, GAL4-
HDAC4, GAL4-HDAC5, or GAL4-HDAC7 cannot interact with
14-3-3-VP16, and the GAL4-dependent UAS-luciferase cannot
be activated (Figure 3A). Expression plasmids encoding these
fusion proteins, together with UAS-luciferase, were transfected
into COS-7 cells together with increasing amounts of PKD1 or
PKD2 expression plasmids. PKD1 and PKD2 increased UAS-
luciferase activity in a dose-dependent manner. These data
indicate that PKD1 and PKD2 create phospho-14-3-3 recognition
motifs in HDAC4, HDAC5, and HDAC7, which recruit 14-3-3
proteins that mediate their nuclear export.
We had identified amino acids 360-601 as PKD1 binding
region in HDAC5 (Du Bois et al., 2015). To test if PKD2
and HDAC5 physically interact as well, we performed co-
immunoprecipitation experiments with PKD2 and wild-type and
deletion mutants of HDAC5. We found that PKD2 interacted
avidly with HDAC5 and that amino acids 360–601 in HDAC5
were responsible for this interaction (Figures 3B,C).
To investigate if PKD1, PKD2, and PKD3 phosphorylate
endogenous HDAC4, HDAC5, and HDAC7 in myocytes,
we transfected the respective PKD expression plasmids
into C2C12 cells and performed Western blot analyses
on proteins isolated from these cells using anti-phospho-
HDAC4 (Ser246)/HDAC5 (Ser259)/HDAC7 (Ser155),
anti-phospho-HDAC4 (Ser632)/HDAC5 (Ser661)/HDAC7
(Ser486), anti-HDAC4, anti-HDAC5, anti-HDAC7, and anti-
glyceraldehyde-3-phosphate dehydrogenase antibodies. PKD1,
PKD2, and PKD3 phosphorylated all three endogenous class
IIa HDACs in C2C12 cells (Supplementary Figure 3A).
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FIGURE 2 | Protein kinase D family members attenuate HDAC-mediated inhibition of TFEB-induced TRIM63 expression. (A–C), COS-7 cells were transfected with
expression plasmids encoding FLAG-TFEB, (A) HDAC4-MYC, (B) HDAC5-MYC, or (C) HDAC7-MYC, or constitutively active (ca) PKD1 (left panel), caPKD2 (middle
panel), and caPKD3 (right panel) proteins, as indicated, together with the Hs_TRIM63_Luc reporter construct (-543 bp). Values were normalized to expression of
CMV-LacZ and calculated as the fold increase in luciferase/CMV-LacZ ratio compared with the reporter alone. Data are represented as mean ± SEM. One-way
ANOVA P < 0.0001 for (A–C); *P < 0.05; **P < 0.01; ***P < 0.005. n = 5. (D) COS-7 cells were transfected with FLAG-TFEB and HDAC4-MYC, HDAC5-MYC, and
HDAC7-MYC together with a pcDNA3.1 control vector or caPKD1, as indicated. Immunostaining was performed with anti-FLAG (green) and anti-MYC (red)
antibodies. Scale bars, 10 µm.
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FIGURE 3 | PKD1 and PKD2 mediate phosphorylation and 14-3-3 binding of class IIa HDACs. (A) COS-7 cells were transfected with upstream activator sequence
(UAS)-luciferase and expression plasmids encoding GAL4 fused with the wild-type (WT) HDAC4 (left panel), HDAC5 (middle panel), or HDAC7 (right panel)
N-terminal extension together with 14-3-3-VP16 and increasing amounts of expression plasmids of constitutively active (ca) PKD1 or caPKD2 (from 6.25 to 400 ng),
as indicated. Values were normalized to expression of CMV-LacZ and calculated as fold increase. Data are represented as mean ± SEM. One-way ANOVA
P < 0.0001 for all; *P < 0.05; **P < 0.01; ***P < 0.005. n = 3. (B), Co-immunoprecipitation (Co-IP) assay with lysates from COS-7 cells expressing FLAG-PKD2 and
deletion mutants of MYC-HDAC5, as indicated. HDAC5 fusion proteins were immunoprecipitated (IP) with anti-MYC antibodies, and PKD2 fusion proteins were
detected with an antibody directed against FLAG. Input proteins were detected by Western blot (immunoblot, IB) with antibodies directed against the FLAG- or
MYC-tag. n = 3. FL indicates full length. (C) Scheme of PKD2 binding site in HDAC5.
We used the pan-PKD inhibitor CID 2011756 to investigate
the specificity of PKD1-mediated HDAC4-, HDAC5-, and
HDAC7-phosphorylation in myocytes. C2C12 myocytes
were transfected with PKD1 or pcDNA and treated with
CID 2011756 (50 µM) or vehicle (dimethyl sulfoxide) for
6 h. Western blot analyses of protein lysates showed that
CID 2011756 attenuated PKD1-mediated phosphorylation
of all three endogenous class IIa HDACs in myocytes
(Supplementary Figure 3B). In summary, these data indicate
that PKD1, PKD2, and PKD3 attenuate the inhibitory effect of
HDAC4, HDAC5, and HDAC7 onto TFEB-induced TRIM63
expression by phosphorylation and 14-3-3 mediated nuclear
export of these HDACs.
Transcription Factor Binding to
Immunoglobulin Heavy-Chain Enhancer
3 but Not Microphthalmia-Associated
Transcription Factor Increase Tripartite
Motif-Containing 63 Expression
Because TFEB and the closely related MiTF-family members
TFE3 and MiTF elicit some degree of functional redundancy
and bind to the same E-box elements (Steingrimsson
et al., 2004; Martina et al., 2014; Pastore et al., 2016),
we hypothesized that TFE3 and MiTF could regulate
TRIM63 expression as well. Indeed, TFEB (Figure 4A)
and TFE3 (Figure 4B) but not MiTF (Figure 4C)
increased TRIM63 activity in a dose-dependent manner.
Thus, for further experiments, we focused on TFE3
and excluded MiTF. Using the wild-type and E-box
mutated TRIM63 reporter constructs (Figure 4D; Du
Bois et al., 2015), we found that the TFE3-induced
TRIM63 expression was strongly reduced in E-box 1 and
E-box 3 mutants, whereas mutation of E-box 2 had a
weaker effect (Figure 4E). These data indicate that E-box
1 and E-box 3 mediate the TFEB- and TFE3-induced
TRIM63 activity.
Transcription Factor EB and
Transcription Factor Binding to
Immunoglobulin Heavy-Chain Enhancer
3 Strongly Interact With Each Other
Because TFEB and TFE3 used the same E-box motives, we
investigated if TFEB and TFE3 have additive functions on the
TRIM63 promoter. We found that equimolar concentrations of
TFEB and TFE3 activated the TRIM63 promoter to comparable
degrees and that their combination did not result in a
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FIGURE 4 | MiTF/TFE family member TFE3 but not MiTF increase TRIM63 expression. (A–C) Luciferase assays performed on cell extracts of COS-7 cells
transfected with Hs_TRIM63-Luc (-543 bp) with increasing amounts of (A) FLAG-TFEB (TFEB), (B) FLAG-TFE3, or (C) FLAG-MiTF as indicated or control (-) plasmid.
Luciferase activity was normalized to expression of CMV-LacZ and expressed as fold increase. Data are represented as mean ± SEM. ***P < 0.005 vs. control
transfection with pcDNA3.1. (D) Schematic diagram of the human TRIM63-promoter. Positions of conserved E-box motifs (CANNTG) relative to the transcription
start site (TSS) are indicated. Homo sapiens (mut.) indicates mutated nucleotides to inactivate individual E-boxes (mutated nucleotides are shown in bold). One-way
ANOVA P < 0.0001 (A,B) and n.s. (C), respectively; *P < 0.05; **P < 0.01; ***P < 0.005. (E) COS-7 cells were transfected with a TFE3 expression plasmid and the
indicated TRIM63-promoter constructs (–543 bp) harboring E-box mutations, as shown in (D). Data are represented as mean ± SEM. *P < 0.05; **P < 0.01;
***P < 0.005. (F) Luciferase assays (Hs_TRIM63-Luc; -543 bp) performed on cell extracts of COS-7 cells after a single transfection with either MYC-TFEB (TFEB) or
FLAG-TFE3 (TFE3) or cotransfection with MYC-TFEB (TFEB) and FLAG-TFE3 (TFE3). Luciferase activity was normalized to expression of CMV-LacZ and expressed
as fold increase. Data are represented as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.005. (G), Co-immunoprecipitation (Co-IP) assay with lysates from COS-7
cells expressing FLAG-TFE3 and MYC-TFEB. TFE3 fusion proteins were immunoprecipitated (IP) with anti-FLAG M2 agarose, and TFEB fusion proteins were
detected with an antibody directed against MYC. Input proteins were detected by Western blot (immunoblot, IB) with antibodies directed against the FLAG- or
MYC-tag. n = 3. During cell lysis and IP increasing concentrations of sodium chloride (50, 100, 300, 500, 700, and 900 mM) were used as indicated.
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further increase in TRIM63 activity (Figure 4F). These data
indicate that TFEB and TFE3 are possibly competing for
the same E-box elements. As TFEB and TFE3 are known
to heterodimerize, we tested the strength of this interaction.
We performed cell lysis and co-immunoprecipitation with
increasing sodium chloride buffer concentrations ranging from
50- to 900-mM sodium chloride. Only the highest sodium
chloride concentration used attenuated the interaction between
TFEB and TFE3, indicative of a strong interaction of both
proteins (Figure 4G).
Class IIa Histone Deacetylases 4, 5, and




We next hypothesized that the activity of TFE3 on the TRIM63
promoter is also inhibited by class IIa HDACs. Using luciferase
assays, we found that HDAC4 (Figure 5A), HDAC5 (Figure 5B),
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FIGURE 5 | Class IIa histone deacetylases 4, 5, and 7 inhibit TFE3-mediated TRIM63 expression. (A–C), Luciferase assays performed on cell extracts of COS-7
cells transfected with Hs_TRIM63-Luc (-543 bp), FLAG-TFE3 (TFE3), and increasing amounts of (A) MYC-HDAC4 (HDAC4), (B) MYC-HDAC5 (HDAC5), or
(C) MYC-HDAC7 (HDAC7) as indicated or control (-) plasmid. Luciferase activity was normalized to expression of CMV-LacZ and expressed as fold increase. Data
are represented as mean ± SEM. One-way ANOVA P < 0.0001 for (A–C); ###P < 0.005 vs. control transfection with pcDNA3.1; *P < 0.05, **P < 0.01,
***P < 0.005 vs. transfection with TFE3 only. (D) Co-IP assay with lysates from COS-7 cells expressing FLAG-TFE3 and MYC-HDAC5. TFE3 fusion proteins were
immunoprecipitated (IP) with anti-FLAG M2 agarose, and HDAC5 fusion proteins were detected with an antibody directed against MYC. Input proteins were
detected by Western blot (immunoblot, IB) with antibodies directed against the FLAG- or MYC-tag. n = 3. (E) Co-IP assay with lysates from COS-7 cells expressing
FLAG-TFE3 and deletion mutants of MYC-HDAC5, as indicated. TFE3 fusion proteins were immunoprecipitated (IP) with anti-FLAG M2 agarose, and HDAC5 fusions
proteins were detected with an antibody directed against MYC. Input proteins were detected by Western blot (immunoblot, IB) with antibodies directed against the
FLAG- or MYC-tag. n = 3. (F), Scheme of TFE3 binding site in HDAC5.
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activity in a dose-dependent manner, indicating that not only
TFEB but also TFE3 is collectively controlled by class IIa
HDACs. In contrast, TFE3-induced TRIM63 activity was not
reduced by HDAC1 or HDAC3 (Supplementary Figure 1B).
We performed co-immunoprecipitation experiments and found
that TFE3 and HDAC5 interacted with each other (Figure 5D).
We next performed co-immunoprecipitation experiments with
TFE3 and wild-type and deletion mutants of HDAC5 to
determine which region within HDAC5 was required for its
interaction with TFE3. We found that amino acids 51–175
of HDAC5 are required for physical interaction with TFE3
and, therefore, define a TFE3 binding site (Figures 5E,F).
We performed immunocytochemistry using antibodies directed
against endogenous TFE3 and endogenous HDAC4, HDAC5,
and HDAC7 and found that these proteins colocalized in C2C12
myocytes indicating that TFE3 interacts with class IIa HDACs in
myocytes (Supplementary Figure 4).
Protein Kinase D Family Members
Attenuate Histone Deacetylase-Mediated




Based on our findings, we hypothesized that the PKD-family
members could abolish the inhibitory effects of HDAC4,
HDAC5, and HDAC7 toward TFE3. To test this hypothesis,
we performed luciferase assays and found that the TFE3-
induced TRIM63 activity was inhibited by HDAC4 (Figure 6A),
HDAC5 (Figure 6B), and HDAC7 (Figure 6C). Importantly,
cotransfection of PKD1 (Figure 6, left panel), PKD2 (Figure 6,
middle panel), or PKD3 (Figure 6, right panel) relieved the
repressive effects of all three HDACs. CamK IV also relieved
the repressive effects of HDAC4, HDAC5, and HDAC7 in
the same assay (Supplementary Figure 2B). To investigate if
the observed effects of the PKD family onto HDAC-mediated
inhibition of TFE3 are due to nuclear export of HDAC4,
HDAC5, or HDAC7, we performed immunocytochemistry
experiments. We observed colocalization of all class IIa
HDACs with TFE3 in the nucleus (Figure 6D). When we
cotransfected with PKD1, HDAC5 (Figure 6D, left panel),
HDAC4 (Figure 6D, middle panel), and HDAC7 (Figure 6D,
right panel) translocated to the cytoplasm, whereas TFE3
remained in the nucleus. These data show that PKD1, PKD2,
and PKD3 attenuated the inhibitory effect of HDAC4, HDAC5,
and HDAC7 onto TFE3-induced TRIM63 expression by nuclear
export of these HDACs.
DISCUSSION
We report that TRIM63 expression is tightly regulated by
a transcriptional network comprised of the PKD-family
members PKD1, PKD2, and PKD3, the class IIa HDACs
HDAC4, HDAC5, and HDAC7, as well as the MiT/TFE
family members TFEB and TFE3. We show that HDAC4,
HDAC5, and HDAC7 colocalize with TFEB and TFE3 in
the nucleus of non-muscle cells and inhibit TFEB- and
TFE3-induced TRIM63 expression. We demonstrate that
PKD1, PKD2, and PKD3 phosphorylate HDAC4, HDAC5,
and HDAC7. This state-of-affairs facilitates their binding to
the 14-3-3 chaperon protein and their consecutive nuclear-
export relieving repression of TFEB- and TFE3-induced
TRIM63 expression. All PKD family members ameliorated
HDAC-mediated inhibition of TFEB- and TFE3-mediated
TRIM63 promoter activity. We conclude that TRIM63
expression, which is a key factor in UPS-dependent protein
degradation in skeletal muscle during atrophy, is regulated at
multiple levels.
Skeletal muscle atrophy is characterized by a reduction
in myofiber size, mainly due to a net loss of structural
proteins leading to a reduced muscle mass and function. As
it occurs in many pathological conditions, such as critical
illness and inflammation, this results from increased UPS-
dependent protein degradation (Hershko and Ciechanover, 1998;
Ciechanover, 2006). However, muscle atrophy is a complex
process that is mediated by multiple factors. Indeed, the
molecules, mediators, and cellular pathways contributing to
muscle atrophy are still being discovered (Bodine and Baehr,
2014). In 2001, Bodine et al. (2001a) identified TRIM63/MuRF1
as an atrogene that was highly upregulated in atrophying muscle
after denervation, immobilization, and unweighting-induced
atrophy in rats. MuRF1/Trim63 knockout mice showed less
denervation-induced muscle atrophy compared with wild-type
mice (Bodine et al., 2001a). Thereafter, we and others confirmed
the involvement of MuRF1 in muscle atrophy (Du Bois et al.,
2015), described its increased expression in physiological and
pathological muscle atrophy (Schmidt et al., 2014; Wollersheim
et al., 2014; Huang et al., 2017), and discovered MuRF1 targets
(Fielitz et al., 2007; Witt et al., 2008; Labeit et al., 2010;
Nowak et al., 2019).
Increased TRIM63 expression is a well-established and
accepted read-out for skeletal muscle atrophy in general.
The expression of MuRF1/TRIM63 is regulated by several
signaling pathways converging onto multiple TFs, such as
the forkhead box protein family (Stitt et al., 2004; Raffaello
et al., 2010) and myogenin (Moresi et al., 2010). Glass
and co-workers demonstrated that the insulin-like growth
factor/phosphoinositide 3-kinase/protein kinase B/Akt pathway,
which had previously been shown to induce hypertrophy (Bodine
et al., 2001b), suppresses atrophy by downregulating MuRF1.
Myogenin was also shown to regulate TRIM63, and mice that lack
myogenin failed to upregulate TRIM63 expression. These mice
were resistant to denervation-induced muscle atrophy (Moresi
et al., 2010). Given the importance of transcriptional regulation
of TRIM63, we previously performed a cDNA expression screen
to identify regulators of TRIM63 expression. We identified TFEB
as an important TF and described its regulation and importance
in muscle atrophy in myocytes in vitro and in muscle in vivo
(Du Bois et al., 2015).
TFEB belongs to the MiT/TFE family of bHLH-LZ TFs,
including TFE3, MiTF, and TFEC (Steingrimsson et al., 2004).
All MiT/TFE TFs recognize a unique E-box motif within the
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FIGURE 6 | Protein kinase D family members attenuate HDAC-mediated inhibition of TFE3-induced TRIM63 expression. (A–C), COS-7 cells were transfected with
expression plasmids encoding FLAG-TFE3, (A) HDAC4-MYC, (B) HDAC5-MYC, or (C) HDAC7-MYC, or constitutively active (ca) PKD1 (left panel), caPKD2 (middle
panel), and caPKD3 (right panel) proteins, as indicated, together with the Hs_TRIM63_Luc reporter construct (-543 bp). Values were normalized to expression of
CMV-LacZ and calculated as the fold increase in luciferase/CMV-LacZ ratio compared with the reporter alone. Data are represented as mean ± SEM. One-way
ANOVA P < 0.0001 for (A–C); *P < 0.05; **P < 0.005. n = 5. (D) COS-7 cells were transfected with FLAG-TFE3 and HDAC4-MYC, HDAC5-MYC, and
HDAC7-MYC together with an empty vector (pcDNA_3.1) or caPKD1, as indicated. Immunostaining was performed with anti-FLAG (green) and anti-MYC (red)
antibodies. Scale bars, 10 µm.
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proximal promoters of lysosomal and autophagy genes (Sardiello
et al., 2009; Palmieri et al., 2011; Martina et al., 2014) and
regulate cellular catabolism and nutrient-dependent lysosomal
response (Settembre et al., 2011; Slade and Pulinilkunnil, 2017).
Within the MiT/TFE family, a close relationship exists between
TFEB and TFE3. TFEB and TFE3 regulate cellular adaptation
to stress by induction of lysosomal biogenesis and autophagy
and immune responses, metabolism, mitochondrial homeostasis,
and unfolded-protein responses. TFEB and TFE3 were shown
to regulate the same genes (Pastore et al., 2016), such as CDH1,
encoding E-cadherin (Huan et al., 2005), CD40L, encoding
CD40 ligand (Huan et al., 2006), and PPARGC1a, encoding
PGC1α (Settembre et al., 2013). However, whether or not TFE3
activates TRIM63 expression was not known. We report that
not only TFEB but also TFE3 regulates TRIM63 expression and
that both TFs are controlled by the PKD and HDAC enzyme
families. To the well-described TFEB and TFE3 functions,
we add that both TFs also regulate TRIM63 expression. We
propose that they activate UPS- and autophagy-mediated protein
degradation. We showed earlier that TFEB regulates TRIM63
expression via binding to E-box elements in the TRIM63
promoter, and mutation of these binding motifs abrogated TFEB-
dependent TRIM63 expression. However, although MiT/TFE
family members bind specific E-box elements and use the same
E-box motifs as TFEB to induce TRIM63 expression, we have not
yet demonstrated direct binding of TFE3 to the native TRIM63
promoter. Such analyses need to be performed.
MuRF1 and the regulation of its expression are important for
metabolic adaptations of striated muscles (Hirner et al., 2008;
Witt et al., 2008; Rudolf et al., 2013). MuRF1 mediates the
degradation of numerous metabolic enzymes, such as pyruvate
dehydrogenase and its regulator pyruvate dehydrogenase kinase
that are key mitochondrial enzymes regulating glycolysis.
Interaction studies also demonstrated that MuRF1 interacts with
pyruvate kinase 2, phosphorylase beta, and glycogenin, which
are involved in glycolysis and glycogen metabolism, respectively
(Hirner et al., 2008). Because TFEB (Mansueto et al., 2017),
TFE3 (Iwasaki et al., 2012), and forkhead box (Schiaffino
et al., 2013) are also involved in muscle metabolism and
mitochondrial homeostasis, these effects are possibly mediated by
their ability to regulate TRIM63 expression. As our conclusions
are mainly based on data obtained from non-muscle cells, this
hypothesis warrants further investigation to show its relevance in
muscle metabolism.
Distinguished by their structures and expression patterns,
HDACs can be divided into different classes. We focused on
the heart and skeletal muscle enriched class IIa HDACs 4, 5,
and 7. All class IIa HDACs repress the activity of myocyte
enhancer factor 2 (MEF2), which reduces the expression of
MEF2 target genes and suppresses the formation of slow-twitch,
oxidative fibers in the muscle (Lu et al., 2000a,b; McKinsey
et al., 2000; Zhang et al., 2002; Potthoff et al., 2007). HDAC4
and HDAC5 coordinately inhibited the activity of myogenin that
is important for myogenesis (Moresi et al., 2010). Latter data
implicated that HDAC4, HDAC5, and HDAC7 predominantly
inhibit bHLH TFs contained in muscle to regulate muscular
stress response. However, if other class IIa HDACs inhibit
TFEB and if they can also reduce TFE3-mediated TRIM63
expression was unknown. We describe that HDAC4, HDAC5,
and HDAC7 inhibit TFEB-mediated TRIM63 activity and show
that all three HDACs inhibited TFE3. We propose that class IIa
HDACs collectively control TRIM63 expression. However, as our
experiments were mainly performed in non-myocytes, further
studies are needed to investigate if this mode of action also
occurs in myocytes.
Protein function is often regulated by reversible protein
phosphorylation by protein kinases, such as the PKD family
(Rykx et al., 2003; Rozengurt, 2011). This family of stress-
responsive serine-threonine kinases of the calmodulin-calcium-
dependent-kinase family (termed PKD1, PKD2, and PKD3) play
important roles in cell growth, differentiation, migration, and
apoptosis (Rozengurt et al., 2005). Importantly, we and others
showed that PKD1 mediates muscle atrophy (Du Bois et al.,
2015), facilitates slow-twitch-fiber transformation in the muscle
(Kim et al., 2008), and mediates cardiac stress response (Fielitz
et al., 2008). However, the close structural relationship of the
PKD family members especially in their functional domains
(Avkiran et al., 2008) suggested that they might phosphorylate
overlapping targets and might be involved in the observed
phenotypes as well. Indeed, PKD1, PKD2, and PKD3 were
all shown to phosphorylate HDAC5 (Huynh and McKinsey,
2006). This situation, in turn, relieves the repression of TFs
such as MEF2 and TFEB (Fielitz et al., 2008; Du Bois et al.,
2015). The mechanism is involved in the pathophysiology of
cardiomyocyte hypertrophy in vitro and cardiac hypertrophy and
remodeling in vivo (Vega et al., 2004; Fielitz et al., 2008). These
observations suggested that PKD family members redundantly
control the activity of class IIa HDACs (Huynh and McKinsey,
2006). However, it was uncertain if this interaction affects
TFEB- or TFE3-mediated TRIM63 expression. We confirmed
this hypothesis for all three PKD family members and show
that they phosphorylate HDAC4, HDAC5, and HDAC7 and
promote their nuclear export. Because a high degree of functional
redundancy was reported for PKD1 and PKD2, we investigated if
PKD2 also interacts with HDAC5. We confirmed this interaction
and mapped the binding of PKD2 to HDAC5 to the same
region in HDAC5 that binds to PKD1, suggesting that TRIM63
expression is redundantly controlled. We also show that PKD3,
which is normally not expressed in unstressed myocytes (Li
et al., 2011), elicits comparable effects toward the control of
TRIM63 expression by class IIa HDACs. This state-of-affair might
especially be important during stress situations where PKD3 was
shown to be strongly increased (Li et al., 2011). Our data are in
line with previous reports showing that PKD3 can substitute for
PKD1 as an HDAC5 kinase in non-muscle cells (Matthews et al.,
2006). In summary, our data indicate that a diverse and multilevel
pathway regulates muscle atrophy.
Subcellular localization of class IIa HDACs is strongly
controlled by several protein kinases, which are not restricted
to the protein kinase D family but also involve CamK I,
CamK IV (also shown here), MARK2, and others (Chang
et al., 2005). Also, some kinases selectively target specific class
IIa HDACs, i.e., CamK II specifically targets HDAC4 (Backs
et al., 2006). These data, together with our findings and the
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known regulation of TFEB and TFE3 activity by posttranslational
modification (Puertollano et al., 2018), indicate that TFEB- and
TFE3-mediated transcriptional activity has a much higher level
of complexity that could not be addressed here and warrants
further studies.
Previous studies showed that TFEB (Settembre et al., 2012)
and TFE3 (Martina et al., 2014) are predominantly localized in
the cytoplasm of HEK-293T and ARPE-19 cells, respectively,
and that their phosphorylation status and cytosolic-to-nuclear
shuttling regulates TFEB and TFE3 activity. The kinases
mammalian target of rapamycin complex 1 (mTORC1) and
ERK are important in that regard (Martina et al., 2012, 2014;
Settembre et al., 2012). In the presence of nutrients, mTORC1
phosphorylates TFEB and TFE3, thereby facilitating their binding
to 14-3-3 chaperone proteins and mediating their retention in
the cytoplasm. Conversely, reduced mTORC1 activity increases
TFEB (Settembre et al., 2012) and TFE3 (Martina et al., 2014)
shuttling into the nucleus. In contrast, in line with our previous
report (Du Bois et al., 2015), we observed that TFEB and
TFE3 were mainly localized to the nucleus of COS-7 cells
when overexpressed. If these observations are attributable to
differences in the cell type, culturing conditions, differentiation
status, or transfection warrants further investigation. However,
our observation that TFEB and TFE3 are localized to the
nucleus is supported by other findings showing that 20–30%
of TFEB is contained in the nucleus of several cell lines, such
as patient-derived fibroblasts (Song et al., 2013), HeLa cells
(Settembre et al., 2011), ARPE-19 cells (Martina et al., 2012),
and mouse embryonic fibroblasts (Sardiello et al., 2009). Because
we hypothesized that HDAC4, HDAC5, and HDAC7 regulate
the activity of TFEB and TFE3 at the TRIM63 promoter, as
reported for their inhibitory effects on MEF2 target genes (Lu
et al., 2000a,b; McKinsey et al., 2000; Zhang et al., 2002),
we used overexpression as a model system despite differences
in subcellular localization of the participating proteins. Our
data indicate that the activity of TFEB and TFE3 is regulated
at least at two different levels, first by regulation of their
subcellular localization and second by repression of their activity
by class IIa HDACs.
LIMITATIONS
Most of the data shown in our study are based on overexpression
experiments. Our results need further evaluation, especially
in myocytes, myotubes, and skeletal muscle, and by working
with the endogenous components of the signaling pathway
described, such as co-staining of endogenous proteins in
immunocytochemistry. Nevertheless, our results are in line with
previously published work that focused on the regulation of
the activity and subcellular localization of class IIa HDACs by
PKD both in vitro (Zhang et al., 2002; Dequiedt et al., 2005;
Backs et al., 2006) and in vivo (Fielitz et al., 2008; Kim et al.,
2008; Du Bois et al., 2015). Although we have shown that upon
coexpression with PKD, HDAC4, HDAC5, and HDAC7 are
localized in the cytoplasm, and PKD increased UAS-luciferase
activity that depends on 14-3-3 binding, we have not proven
that this export was mediated by CRM1. Likewise, to illustrate
our findings, we display representative pictures of single nuclei
and have not performed biochemical fractionation experiments
(nuclear vs. cytosolic extracts) to support the nuclear export of
the HDACs upon PKD1 overexpression for a larger subset of cells.
Because such experiments have been performed previously, we
would like to refer to this work (Harrison et al., 2004; Vega et al.,
2004). We have used co-immunoprecipitation experiments to
show the interaction of PKD1 and PKD2 with HDAC5, mapped
the interacting domains, and showed functional consequences
of these interactions. We have also shown that the activity of
TFEB and TFE3 on the TRIM63 reporter is inhibited by class
IIa HDACs. However, further studies are needed to prove that
these proteins directly interact which each other by using cell-
free assays, proximity ligation assays, coimmunostaining, or
other techniques.
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